The effectiveness of Keytruda varies depending on the type and stage of cancer. Clinical trials have shown significant improvement in overall survival and progression-free survival in patients with certain cancers, particularly those with high PD-L1 expression. The drug has also demonstrated durable responses in some cases, meaning that patients may experience long-term benefits even after treatment has ended.